Hemin

Summary

Hemin (CHEMBL1200662) is a phase-3 clinical-stage small molecule; indicated across 6 conditions including myelodysplastic syndrome and acute pancreatitis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 6 conditions
• Clinical trials: 5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200662
Name	Hemin
Type	Small molecule
Max phase	3

Also known as: Hemin, NSC-122707, HEMIN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
myelodysplastic syndrome	2	MONDO:0018881	EFO:0000198
acute pancreatitis	2	MONDO:0006515	EFO:1000652
hereditary coproporphyria	2	MONDO:0007369	MONDO:0007369
acute intermittent porphyria	2	MONDO:0008294	MONDO:0008294
variegate porphyria	2	MONDO:0008297	MONDO:0008297
porphyria	2	MONDO:0037939	MONDO:0037939

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE2	3
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01206582	PHASE2	COMPLETED	A Pilot Study of Hemin Therapy for Gastroparesis (Diabetes Mellitus)
NCT01855841	PHASE2	COMPLETED	Hemin to Prevent Post-ERCP (Endoscopic Retrograde Cholangiopancreatography) Acute Pancreatitis
NCT02922413	PHASE2	TERMINATED	Panhematin for Prevention of Acute Attacks of Porphyria
NCT00882804	PHASE1	COMPLETED	Hemin in Healthy Subjects
NCT02935400	Not specified	ACTIVE_NOT_RECRUITING	Acute Porphyria Biomarkers for Disease Activity

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).